Japan To Link Global Drug Trials To Enable 18-Month Approvals
This article was originally published in PharmAsia News
Japan's Health Ministry plans to take action to speed drug approval by loosening some of its regulations, possibly including creation of a "global clinical trial institution." The agency is considering the action in recognition of the trend of an increasing number of drug makers to conduct trials in several countries at the same time. The ministry seeks to make the Japanese process comparable to those of its counterparts in the U.S. and Europe. The global institution is seen as a way for the government to meet its five-year plan launched last year to cut drug-approval time to about 18 months, compared with the four years the process requires today. (Click here for more - a subscription may be required
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.